Overactive bladder

Maturitas

Volumn 66, Issue 3, 2010, Pages 257-262

  Henderson, Emily ^a   Drake, Marcus ^a  

^a NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

Detrusor overactivity; Overactive bladder; Urinary incontinence

Indexed keywords

BETA 3 ADRENERGIC RECEPTOR; BOTULINUM TOXIN A; CAPSAICIN; DARIFENACIN; ION CHANNEL; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; POTASSIUM CHANNEL STIMULATING AGENT; RESINIFERATOXIN; TERODILINE; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TROSPIUM CHLORIDE;

BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FLOW RATE; GENETIC PREDISPOSITION; HUMAN; MICTURITION; NERVE STIMULATION; NEUROMODULATION; OVERACTIVE BLADDER; PATHOGENESIS; PREVALENCE; QUALITY OF LIFE; RESIDUAL VOLUME; REVIEW; SENSORY NERVE; TACHYCARDIA; URINARY URGENCY; URODYNAMICS; XEROSTOMIA;

HUMANS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 77953024337     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.03.010     Document Type: Review

References (54)

1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 21 2 (2002) 167-178
2. Hashim H., and Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity?. J Urol 175 January (1) (2006) 191-194 [discussion 4-5]
3. Bristow S.E., and Neal D.E. Ambulatory urodynamics. Br J Urol 77 March (3) (1996) 333-338
4. Garnett S., Swithinbank L., Ellis-Jones J., and Abrams P. The long-term natural history of overactive bladder symptoms due to idiopathic detrusor overactivity in women. BJU Int April (2009)
5. Irwin D.E., Milsom I., Hunskaar S., et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50 December (6) (2006) 1306-1314 [discussion 14-5]
6. Stewart W.F., Van Rooyen J.B., Cundiff G.W., et al. Prevalence and burden of overactive bladder in the United States. World J Urol 20 May (6) (2003) 327-336
7. Brown J.S., Vittinghoff E., Wyman J.F., et al. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group. J Am Geriatr Soc 48 July (7) (2000) 721-725
8. Gentili A., Weiner D.K., Kuchibhatil M., and Edinger J.D. Factors that disturb sleep in nursing home residents. Aging (Milano) 9 June (3) (1997) 207-213
9. Zorn B.H., Montgomery H., Pieper K., Gray M., and Steers W.D. Urinary incontinence and depression. J Urol 162 July (1) (1999) 82-84
10. Irwin D.E., Abrams P., Milsom I., Kopp Z., and Reilly K. Understanding the elements of overactive bladder: questions raised by the EPIC study. BJU Int 101 June (11) (2008) 1381-1387
11. Reeves P., Irwin D., Kelleher C., et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 50 November (5) (2006) 1050-1057
12. Wagner T.H., and Hu T.W. Economic costs of urinary incontinence. Int Urogynecol J Pelvic Floor Dysfunct 9 3 (1998) 127-128
13. Hannestad Y.S., Lie R.T., Rortveit G., and Hunskaar S. Familial risk of urinary incontinence in women: population based cross sectional study. BMJ 329 October (7471) (2004) 889-891
14. Fitzgerald M.P., Thom D.H., Wassel-Fyr C., et al. Childhood urinary symptoms predict adult overactive bladder symptoms. J Urol 175 March (3 Pt 1) (2006) 989-993
15. Dallosso H.M., Matthews R.J., McGrother C.W., Donaldson M.M., and Shaw C. The association of diet and other lifestyle factors with the onset of overactive bladder: a longitudinal study in men. Public Health Nutr 7 October (7) (2004) 885-891
16. Andersson K.E. Bladder activation: afferent mechanisms. Urology 59 May (5 Suppl. 1) (2002) 43-50
17. de Groat W.C. A neurologic basis for the overactive bladder. Urology 50 December (6A Suppl.) (1997) 36-52 [discussion 3-6]
18. Brading A.F., and Turner W.H. The unstable bladder: towards a common mechanism. Br J Urol 73 January (1) (1994) 3-8
19. Brading A.F. Spontaneous activity of lower urinary tract smooth muscles: correlation between ion channels and tissue function. J Physiol 570 January (Pt 1) (2006) 13-22
20. Drake M.J., Mills I.W., and Gillespie J.I. Model of peripheral autonomous modules and a myovesical plexus in normal and overactive bladder function. Lancet 358 August (9279) (2001) 401-403
21. Drake M.J. The integrative physiology of the bladder. Ann R Coll Surg Engl 89 September (6) (2007) 580-585
22. Andersson K.E. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn 29 1 (2010) 97-106
23. Griffiths D., Tadic S.D., Schaefer W., and Resnick N.M. Cerebral control of the bladder in normal and urge-incontinent women. Neuroimage 37 August (1) (2007) 1-7
24. Griffiths D.J., Tadic S.D., Schaefer W., and Resnick N.M. Cerebral control of the lower urinary tract: how age-related changes might predispose to urge incontinence. Neuroimage May (2009)
25. Drake M.J., Fowler C.J., Griffiths D., Mayer E., Paton J.F.R., and Birder L. Neural control of the lower urinary and gastrointestinal tracts: supraspinal CNS mechanisms. Neurourol Urodyn 29 1 (2010) 119-127
26. Abrams P., and Klevmark B. Frequency volume charts: an indispensable part of lower urinary tract assessment. Scand J Urol Nephrol Suppl 179 (1996) 47-53
27. Starkman J.S., and Dmochowski R.R. Urgency assessment in the evaluation of overactive bladder (OAB). Neurourol Urodyn 27 1 (2008) 13-21
28. Abrams P., Avery K., Gardener N., and Donovan J. The International Consultation on Incontinence Modular Questionnaire: www.iciq.net. J Urol 175 March (3 Pt 1) (2006) 1063-1066 [discussion 6]
29. Abrams P., Andersson K.E., Birder L., et al. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn 29 1 (2010) 213-240
30. Wallace S.A., Roe B., Williams K., and Palmer M. Bladder training for urinary incontinence in adults. Cochrane Database Syst Rev 1 (2004) CD001308
31. Burgio D.E., Gosland M.P., and McNamara P.J. Effects of P-glycoprotein modulators on etoposide elimination and central nervous system distribution. J Pharmacol Exp Ther 287 December (3) (1998) 911-917
32. Ouslander J.G., Ai-Samarrai N., and Schnelle J.F. Prompted voiding for nighttime incontinence in nursing homes: is it effective?. J Am Geriatr Soc 49 June (6) (2001) 706-709
33. Ouslander J.G., Schnelle J.F., Uman G., et al. Does oxybutynin add to the effectiveness of prompted voiding for urinary incontinence among nursing home residents? A placebo-controlled trial. J Am Geriatr Soc 43 June (6) (1995) 610-617
34. Mansfield K.J., Liu L., Mitchelson F.J., Moore K.H., Millard R.J., and Burcher E. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharmacol 144 April (8) (2005) 1089-1099
35. Gillespie J.I., Harvey I.J., and Drake M.J. Agonist- and nerve-induced phasic activity in the isolated whole bladder of the guinea pig: evidence for two types of bladder activity. Exp Physiol 88 May (3) (2003) 343-357
36. Yamanishi T., Chapple C.R., and Chess-Williams R. Which muscarinic receptor is important in the bladder?. World J Urol 19 November (5) (2001) 299-306
37. Andersson K.E., Chapple C.R., Cardozo L., et al. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol 19 July (4) (2009) 380-394
38. Roxburgh C., Cook J., and Dublin N. Anticholinergic drugs versus other medications for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4 (2007) CD003190
39. Rapp D.E., Neil N.J., Govier F.E., and Kobashi K.C. Bladder sensation measures and overactive bladder. J Urol 182 September (3) (2009) 1050-1054
40. Wang A.C., Chen M.C., Kuo W.Y., Lin Y.H., Wang Y.C., and Lo T.S. Urgency-free time interval as primary endpoint for evaluating the outcome of a randomized OAB treatment. Int Urogynecol J Pelvic Floor Dysfunct 20 July (7) (2009) 819-825
41. Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., and Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 54 September (3) (2008) 543-562
42. Abrams P., Kaplan S., De Koning Gans H.J., and Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 175 March (3 Pt 1) (2006) 999-1004 [discussion]
43. Katz I.R., Sands L.P., Bilker W., DiFilippo S., Boyce A., and D'Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 46 January (1) (1998) 8-13
44. Kay G.G., and Ebinger U. Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin. Int J Clin Pract 62 November (11) (2008) 1792-1800
45. Serati M., Salvatore S., Uccella S., Cardozo L., and Bolis P. Is there a synergistic effect of topical oestrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity?. Eur Urol 55 March (3) (2009) 713-719
46. van Kerrebroeck P.E., van Voskuilen A.C., Heesakkers J.P., et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study. J Urol 178 November (5) (2007) 2029-2034
47. Govier F.E., Litwiller S., Nitti V., Kreder Jr. K.J., and Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol 165 April (4) (2001) 1193-1198
48. Kumar S.P., and Abrams P.H. Detrusor myectomy: long-term results with a minimum follow-up of 2 years. BJU Int 96 August (3) (2005) 341-344
49. Schurch B. Botulinum toxin for the management of bladder dysfunction. Drugs 66 10 (2006) 1301-1318
50. Duthie J., Wilson D.I., Herbison G.P., and Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 3 (2007) CD005493
51. Shaban A.M., and Drake M.J. Botulinum toxin treatment for overactive bladder: risk of urinary retention. Curr Urol Rep 9 November (6) (2008) 445-451
52. Andersson K.E., Uckert S., Stief C., and Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn 26 October (6 Suppl.) (2007) 928-933
53. Langtry H.D., and McTavish D. Terodiline. A review of its pharmacological properties, and therapeutic use in the treatment of urinary incontinence. Drugs 40 November (5) (1990) 748-761
54. Streng T., Christoph T., and Andersson K.E. Urodynamic effects of the K+ channel (KCNQ) opener retigabine in freely moving, conscious rats. J Urol 172 November (5 Pt 1) (2004) 2054-2058